PitchSend

Nuvectis Pharma Investor Presentation Deck

Loss of ARID1a Sensitizes Cells to NXP800-induced Apoptosis Isogenic HCT116 Cell Model Wildtype Heterozygote Homozygote 0 2 6 24 0 2 6 24 0 2 6 24 Paul Workman, Molecular targets and Cancer Therapeutics, oral presentation, 2023 NuvectisPharma, Inc. ATF4 ATF3 CHAC1 Cleaved PARP Activation of the ATF4/ATF3/ CHAC1 cascade in the ARID1A wildtype, heterozygote and homozygote HCT116 human colorectal cancer cells. * Expression of cleaved PARP, an apoptotic marker, is markedly induced only in heterozygote and homozygote ARID1a mutant HCT116 cells 8

View entire presentation